Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Inhibitors Of Virion Release01:25

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
Inhibitors of Virion Maturation and Assembly01:19

Inhibitors of Virion Maturation and Assembly

As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evidence Supporting Utility of the Oral Cholate Challenge Test of Liver Function and Physiology to Aid Clinical Management: A Review of Analytical and Clinical Validation Studies.

Gastro hep advances·2026
Same author

Beyond Liver Function Tests, Liver Stiffness, and Portal Pressure: Portal-Systemic Shunting as a New Endpoint for Clinical Trials of Cirrhosis and Portal Hypertension.

Gastro hep advances·2026
Same author

Simultaneous quantification of native human and transgenic porcine liver function in a decedent model of extracorporeal cross-circulation.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
Same author

When should I repeat the endoscopy in my patient with compensated cirrhosis, whom I just scoped and who had no or small varices?

Translational gastroenterology and hepatology·2026
Same author

Extracorporeal liver cross-circulation using transgenic xenogeneic pig livers with brain-dead human decedents.

Nature medicine·2026
Same author

Utilization of the Disease Severity Index (DSI) from the HepQuant DuO Test Enhances Clinical Decision Making in Compensated Advanced Chronic Liver Disease.

Journal of clinical medicine·2026

Related Experiment Video

Updated: Jun 21, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

HCV NS5B polymerase inhibitors.

James R Burton1, Gregory T Everson

  • 1Department of Medicine, Division of Gastroenterology and Hepatology, University of Colorado, Denver, Aurora, CO 80045, USA. james.burton@ucdenver.edu

Clinics in Liver Disease
|July 25, 2009
PubMed
Summary

Chronic hepatitis C virus (HCV) infection impacts millions, with current treatments showing limited success. New polymerase inhibitors offer promise for future hepatitis C virus therapy, especially for challenging patient groups.

More Related Videos

Reverse Genetics to Engineer Positive-Sense RNA Virus Variants
15:49

Reverse Genetics to Engineer Positive-Sense RNA Virus Variants

Published on: June 9, 2022

Related Experiment Videos

Last Updated: Jun 21, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Reverse Genetics to Engineer Positive-Sense RNA Virus Variants
15:49

Reverse Genetics to Engineer Positive-Sense RNA Virus Variants

Published on: June 9, 2022

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Chronic hepatitis C virus (HCV) infection impacts 4 million individuals in the US.
  • HCV is a leading cause for liver transplantation.
  • Current standard treatment (pegylated interferon and ribavirin) achieves a 50% cure rate.

Purpose of the Study:

  • To evaluate the potential of polymerase inhibitors in treating chronic hepatitis C virus (HCV) infection.
  • To assess the role of novel antiviral drugs in managing difficult-to-treat HCV patient populations.

Main Methods:

  • Review of current treatment standards for HCV.
  • Analysis of the antiviral efficacy of polymerase inhibitors.
  • Identification of patient subgroups with challenging treatment outcomes.

Main Results:

  • Current HCV treatments have limited efficacy, with only 50% of patients achieving viral clearance.
  • Polymerase inhibitors demonstrate potent antiviral effects.
  • The efficacy of polymerase inhibitors in non-responders, HIV co-infected, decompensated liver disease, and transplant recipients is yet to be determined.

Conclusions:

  • Polymerase inhibitors represent a significant advancement in the development of hepatitis C virus therapies.
  • Further research is required to establish the role of these novel agents in treating complex HCV cases.